No black box warning on record for Rybrevant Faspro

As of the latest FDA labeling reviewed, Rybrevant Faspro (AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT)) does not carry a black box warning. Standard warnings and precautions still apply — see the full Rybrevant Faspro medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity and Administration-Related Reactions (ARR) : Premedicate with antihistamines, antipyretics, and glucocorticoids. Monitor patients for any signs and symptoms of ARRs. Resume treatment upon resolution of symptoms or permanently discontinue RYBREVANT FASPRO based on severity. ( 2.8 , 5.1 ) Interstitial Lung Disease (ILD)/Pneumonitis : Monitor for new or wor

No black box warning on record for Rybrevant Faspro

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity and Administration-Related Reactions (ARR) : Premedicate with antihistamines, antipyretics, and glucocorticoids. Monitor patients for any signs and symptoms of ARRs. Resume treatment upon resolution of symptoms or permanently discontinue RYBREVANT FASPRO based on severity. ( 2.8 , 5.1 ) Interstitial Lung Disease (ILD)/Pneumonitis : Monitor for new or wor

Rybrevant Faspro Black Box Warning

No black box warning on record for Rybrevant Faspro

Other warnings & precautions

Rybrevant Faspro Black Box Warning

No black box warning on record for Rybrevant Faspro

Other warnings & precautions